At the forefront of the cultured meat revolution, MeaTech develops 3D bioprinting technologies to produce premium industrial animal cell-based meat cuts as a sustainable alternative to industrialized farming. In just two years, the Israeli company went from startup to becoming a publicly traded company on the Nasdaq exchange. Now MeaTech has announced a partnership with a collective led by two renowned technology investors, actor Ashton Kutcher and entertainment manager Guy Oseary.
The entrepreneurial partnership will focus on accelerating the company’s development and commercialization of its proprietary cultured meat production technologies. MeaTech is creating a sustainable alternative to industrialized animal farming by developing its proprietary cultured meat production processes based on advanced 3D bioprinting and tissue engineering technologies for various species offerings.
Kutcher described the initiative as “in line” with his group’s mission to provide sustainable solutions through company building, investment, and acceleration of companies and technologies across various sustainability domains. He expects MeaTech will become the market leader in cultured meat production thanks to its innovative 3D printing processes.
“We intend to work closely with MeaTech’s management to help MeaTech implement its strategy and achieve its goals and global success by leveraging our marketing, strategic expertise, and network,” commented Kutcher, who has been investing in some of the most successful technology startups for over a decade. The celebrity is a founding partner of A-Grade Investments and Sound Ventures and a philanthropist, having founded the anti-human trafficking nonprofit Thorn to help fight the sexual exploitation of children.
MeaTech believes cultured meat technologies hold significant potential to improve meat production, simplify the meat supply chain, and offer consumers a range of new product offerings. Like other competing startups in this niche cultured meat market, the business is relying on bioprinting to create alternative meats, particularly premium, center-of-plate meat products, such as structured marbled steaks.
But the company is not stopping at red meat alternatives. In 2021, MeaTech revealed plans to establish, own, and operate a pilot plant to scale up cultured chicken fat production in 2022. By leveraging its cultured chicken fat technologies, it aims to expedite its market entry while developing, in tandem, an industrial process for cultivating and producing real meat cuts, such as steak or chicken breast, using 3D bioprinting. Ultimately, MeaTech plans to incorporate its 3D bioprinting technologies in the pilot plant to manufacture real meat cuts from cellular agriculture.
Additionally, it is expanding its research and development activities to include pork as part of its strategy to develop a broad cellular agriculture technology offering. Porcine cellular agriculture, if successfully developed, has the potential to expand MeaTech’s potential addressable markets, as pork is the most consumed meat across the globe. According to the United Nations Food and Agriculture Organization (FAO), roughly 36% of the global population eats pork, followed by poultry (33%) and beef (24%).
Working towards these goals, MeaTech CEO Sharon Fima says his company has not only been developing a suite of high-throughput bioprinting systems to produce cell-based alternative protein products, but he has also expressed a vision of creating a cultured meat “factory of the future.” The site would comprise the inputs, processes, and equipment underlying a flexible cultured meat manufacturing facility.
To meet future demand for meat consumption, expected to double by 2050, MeaTech’s Business Development Executive Simon Fried said there will be a need to “grow more food in the next 30 years than in all of human history.” But making meat production sustainable means the industry needs to adopt new cellular-agriculture technologies, and that’s where companies like MeaTech come in.
The key to its success is growing cells in the lab, which are then differentiated into fat and muscle cells. First, the scientists collect samples of umbilical cords from newborn calves without harming the animals. Once differentiated, the cells are placed in bioreactors to grow. Then the cell lines and unique scaffolding materials are transformed into bioinks and loaded into the company’s 3D bioprinter, which will assemble cells as they would be found in a conventional cut of muscle. Finally, the printed product is incubated to mature and form tissue before turning it into a meat cut.
Eventually, the goal is to standardize this process and make it industrial. Fima believes that the new strategic collaboration with the visionary group led by Kutcher and Oseary will accelerate the company’s journey to becoming the next meat production powerhouse. “We will leverage their expertise and relationships with key industry players to help us propel our strategy, go-to-market activities, and brand.”
You May Also Like
One 3D Printing Nozzle, Many Diameters: New from Sculpman
In material extrusion, you’ve traditionally been tied to one nozzle geometry and size. Ideally, you may want to have a larger nozzle to make large interior areas and a finer...
Essentium CEO Discusses High Speed 3D Printing’s Rapid Rise at RAPID+TCT 2021
Essentium, Inc. is one of the fastest developing startups in the fused filament fabrication (FFF) space, in that it is quickly rolling out advanced technology while also growing beyond the...
BASF Opens New 3D Printing Center in Detroit
The world’s largest chemical company, BASF, is growing rapidly within the 3D printing industry through its Forward AM brand. After cutting the ribbon on an Additive Manufacturing Technical Center in...
XYZprinting and BASF Forward AM Extends Industrial Partnership to Enrich 3D Printing Industry
Earlier in the year, XYZprinting and BASF Forward AM established a successful partnership, now the cooperation is realized across all 3D printing portfolios. “The strengthened collaboration between XYZprinting and BASF...
View our broad assortment of in house and third party products.